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Introduction: Although frequent in NSCLC, patients with
brain metastases (BMs) are often excluded from immune
checkpoint inhibitor (ICI) trials. We evaluated BM outcome
in a less-selected NSCLC cohort.
Methods: Data from consecutive patients with advanced ICI-
treatedNSCLCwere collected. Active BMsweredefinedasnew
and/or growing lesions without any subsequent local treat-
ment before the start of ICI treatment. Objective response rate
(ORR), progression-free survival, and overall survival (OS)
were evaluated. Multivariate analyses were performed by us-
ing a Cox proportional hazards model and logistic regression.
Results: A total of 1025 patients were included; the median
follow-up time from start of ICI treatment was 15.8 months.
Of these patients, 255 (24.9%) had BMs (39.2% active,
14.3% symptomatic, and 27.4% being treated with ste-
roids). Disease-specific Graded Prognostic Assessment (ds-
GPA) score was known for 94.5% of patients (35.7% with a
score of 0–1, 58.5% with a score of 1.5–2.5, and 5.8% with a
score of 3). The ORRs with BM versus without BM were
similar: 20.6% (with BM) versus 22.7% (without BM) (p ¼
0.484). The intracranial ORR (active BM with follow-up
brain imaging [n ¼ 73]) was 27.3%. The median
progression-free survival times were 1.7 (95% confidence
interval [CI]: 1.5–2.1) and 2.1 (95% CI: 1.9–2.5) months,
respectively (p ¼ 0.009). Of the patients with BMs, 12.7%
had a dissociated cranial-extracranial response and two
(0.8%) had brain pseudoprogression. Brain progression
occurred more in active BM than in stable BM (54.2%
versus 30% [p < 0.001]). The median OS times were 8.6
months (95% CI: 6.8–12.0) with BM and 11.4 months (95%
CI: 8.6–13.8) months with no BM (p ¼ 0.035). In the BM
subgroup multivariate analysis, corticosteroid use (hazard
ratio [HR] ¼ 2.37) was associated with poorer OS, whereas
stable BMs (HR ¼ 0.62) and higher ds-GPA classification
(HR ¼ 0.48–0.52) were associated with improved OS.
Conclusion: In multivariate analysis BMs are not associated
with a poorer survival in patients with ICI-treated NSCLC.
Stable patients with BM without baseline corticosteroids
and a good ds-GPA classification have the best prognosis.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: NSCLC; Checkpoint inhibition; Brain metastases;
survival; Disease specific Graded Prognostic AssessmentIntroduction
In up to 40% of molecularly unselected patients with
NSCLC, brain metastases (BMs) are diagnosed during the
course of their disease.1 Despite this high incidence,
patients with untreated and/or unstable BMs, or even all
BMs, were excluded from most pivotal immune check-
point inhibitor (ICI) trials.2–13 Use of corticosteroids
(which might abrogate an immune response), the prob-
able inability to cross the blood-tumor barrier (although
the peripherally activated T cell can cross the
blood-tumor barrier), and the risk of brain pseudo-
progression were possible reasons to exclude these pa-
tients.14,15 As a result, patients with BMs were
underrepresented in trials, comprising from 6.2% to
17.5% of enrolled patients.2–9,13 Moreover, patients
were not stratified according to the presence of BMs, and
only a few trials had a preplanned BM subgroup anal-
ysis.2,3,5,9 In the first line KEYNOTE-024 trial (pem-
brolizumab versus platinum-doublet chemotherapy)5
and in the second line CheckMate 017 and 057 trials
(nivolumab versus docetaxel),2,3,16 the survival of pa-
tients with BMs was not significantly superior with ICI
treatment versus with chemotherapy. Conversely, in the
first-line KEYNOTE-189 trial (pembrolizumab platinum-
doublet chemotherapy versus platinum-doublet chemo-
therapy)9 and the second-line OAK trial (atezolizumab
versus docetaxel),17 patients with ICI-treated BMs had a
longer overall survival (OS) than did patients with
chemotherapy-treated BMs. So far, only one prospective
phase II trial with pembrolizumab has specifically
addressed the question of ICI efficacy for patients with
BMs: a 29.4% intracranial objective response rate (ORR)
was observed in the programmed death ligand 1 (PD-
L1)-positive cohort (n ¼ 34), which was similar to the
extracranial ORR.18 Therefore, ICI treatment might also
result in favorable outcomes for patients with NSCLC
and BMs, but data on larger, less-selected cohorts are
needed.
Available series on patients with BMs treated with an
ICI in daily practice mainly come from expanded access
programs (EAPs) or from small retrospective series.19–27
The EAP cohorts have the same biases as the randomized
trials, as they generally required BMs to be treated,
stable, and asymptomatic.23,24 As a result, many ques-
tions, such as the prognostic value of the disease-specific
Graded Prognostic Assessment (ds-GPA) classification
1246 Hendriks et al Journal of Thoracic Oncology Vol. 14 No. 7(Supplementary Table 1)28 or the optimal timing of
cranial irradiation, remain unsolved.
In this study, we aimed to compare outcome of less-
selected patients with ICI-treated NSCLC and BMs with
outcome of patients without BMs and to identify prog-
nostic factors.Patients and Methods
Prospectively collected lists of patients with
advanced NSCLC that started between November 2012
and May 2018 with ICI treatment in six European cen-
ters (five French and one Dutch) were merged. All
consecutive patients with advanced NSCLC were
included when they were treated with programmed cell
death 1 (PD-1)/PD-L1 inhibitors with or without anti–
cytotoxic T-lymphocyte antigen 4 within routine clin-
ical care, EAPs, compassionate use programs, and clinical
trials. Patients were excluded when they were treated
with a concurrent combination of anti–PD-1/PD-L1
therapy and chemotherapy. Patients with lep-
tomeningeal metastases (LMs) were excluded, as the
prognosis of patients with LMs is usually poorer than
that of patients with BMs.29 These patients will be re-
ported separately.
Data on demographics and clinical, pathological, and
molecular data were retrospectively extracted from the
medical records between November 2017 and April
2018. For patients with a diagnosis of central nervous
system metastases, ds-GPA score at the start of ICI
treatment was also collected. The ds-GPA scores were
grouped according to Sperduto et al. as follows: 0 to 1
(worst prognostic group), 1.5 to 2.5, 3, and 3.5 to 4 (best
group).28
Active BMs were defined as newly diagnosed and
nonirradiated lesions and/or growing lesions (investi-
gator/local radiologist–assessed) on brain imaging
(including treated lesions that secondarily progressed)
without any subsequent local treatment before the start
of ICI treatment (compare with Goldberg et al.30). Stable
BMs were defined as those that had been treated (with
radiotherapy or surgery) before ICI treatment and
showed no progression on brain imaging no more than 6
weeks before the start of ICI treatment. Treated patients
with BMs who were symptomatic but had stable or
decreasing symptoms at the start of ICI treatment were
classified as stable.
Data for local assessment of PD-L1 expression were
analyzed on tumor cells by immunohistochemistry.
Expression of at least 1% was considered positive.
Radiological assessments of brain and extracranial dis-
ease were performed (usually every 6–9 weeks), and
response was determined locally at each institution by
the investigator.This study was approved by the institutional review
board of Gustave Roussy (Institutional Review Board)
and the ethical committee of Maastricht University
Medical Centerþ (No. 2018-0530). Informed consent
was not necessary, as clinical and imaging data were
retrospectively added.
Statistical Analysis
Comparisons between patient characteristics were
performed by using the chi-square or Fisher exact test for
discrete variables and the unpaired t test, Wilcoxon signed
rank test, or analysis of variance for continuous variables
when applicable. Disease control rate (DCR) was defined
as complete plus partial response plus stable disease, and
ORR as complete response plus partial response. OS was
calculated from the date of first administration of immu-
notherapy until death due to any cause. Progression-free
survival (PFS) was calculated from the date of first
administration of immunotherapy until progressive dis-
ease (PD) or death due to any cause. A Cox proportional
hazards regression model was used to evaluate factors
independently associated with OS and PFS. Variables
included in the final multivariate model were selected
according to their clinical relevance and statistical signif-
icance in a univariate analysis (cutoff p ¼ .10).
The proportional hazard hypothesis was verified by
using the Schoenfeld residual method. Correlation be-
tween variables was verified before construction of the
multivariate models to deal with potential colinearity.
Statistical analyses were performed with RStudio
software.
Results
Population with BMs
Data on 1052 patients were collected. Of these pa-
tients, 11 were excluded because of combination anti–
PD-1/PD-L1 with chemotherapy and 16 were excluded
because of LMs (with or without BMs) at the start of ICI
treatment, resulting in 1025 included patients (CON-
SORT diagram [Fig. 1]). The median follow-up time was
15.8 (95% confidence interval [95% CI]: 14.6–17.0)
months. A total of 534 patients (52.1%) had brain im-
aging no more than 6 weeks before the start of ICI
treatment; 172 (32.2%) underwent magnetic resonance
imaging, whereas the others underwent computed to-
mography. Reasons for brain imaging were screening,
follow-up of known BMs, and neurological symptoms.
In all, 255 patients (24.9%) had BMs at the start of
ICI treatment. Baseline characteristics for those with and
without BM are presented in Table 1. Compared with
patients without BMs, those with BMs were significantly
younger, had the adenocarcinoma histologic type more
often, had a WHO performance status (PS) of 2 or higher,
Advanced NSCLC patients treated
with ICI
N=1052
BM at start of ICI
N=255
Included in analysis
N=1025
No BM at start of ICI
N= 770
Excluded : ICI concurrent 
with chemotherapy
N = 11
Excluded : LM paents
N = 16
Stable BM
N= 121
Acve BM
N= 100
BM status unknown
N= 34
Figure 1. CONSORT diagram: patient inclusion. ICI: immune checkpoint inhibitor; LM: leptomeningeal metastasis; BM: brain
metastasis.
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more frequently, and had a higher median number of
organs with metastases.
Details on patients with BMs are shown in Table 2. In
all, 37 patients (14.3%) had symptomatic BMs at the
start of ICI treatment and 69 (27.4%) received
corticosteroids.
ds-GPA classification was available for 241 of 255
patients (94.5%); and was 0 to 1 in 86 patients (35.7%),
1.5 to 2.5 in 141 (58.5%), and 3 in 14 (5.8%). None of
the patients had a score of 3.5 or 4. Patients with a lower
ds-GPA classification used corticosteroids at the start of
ICI treatment significantly more often (38.8% with a ds-
GPA classification of 0 to 1, 23.4% with a ds-GPA clas-
sification of 1.5–2.5, and 0% with a ds-GPA classification
of 3 [p ¼ 0.003]). Of the 255 patients, 100 (39.2%) had
active BMs at the start of ICI treatment, 121 (47.5%) had
stable BMs, and BM status (i.e., active or not) was un-
known for 34 (13.3%).Outcome with ICI Treatment
Responses. Overall ORR was not significantly different
for patients with (n ¼ 255) and without (n ¼ 770) BMs:
20.6% versus 22.7% (p ¼ 0.484), but DCR was signifi-
cantly lower in patients with BMs: 43.9% versus 52.0%
(p ¼ 0.024). Of 100 patients with active BMs, 73 (73.0%)
underwent brain imaging during ICI treatment. Theintracranial ORR was 27.3%, and intracranial DCR was
60.3%. For 23 patients with active BMs with baseline
brain imaging and comparable brain imaging available
during ICI treatment (31.5% [i.e., only magnetic reso-
nance imaging or only computed tomography]), PD-L1
status was available; 14 patients (60.9%) had a PD-L1
expression level of 1% or higher, with an ORR of
35.7% versus 11.1% in PD-L1–negative patients. Of the
27 patients with active BMs, three (11.1%) without brain
imaging during ICI treatment died with neurological
deterioration during ICI treatment.
Only two patients with BMs (0.8%) experienced
pseudoprogression in the brain (growing and/or new
BMs on imaging, with subsequent shrinkage on imag-
ing). Nine patients with BMs had resection of a BM
during ICI treatment because of symptomatic growth.
For one patient, radiological growth was comparable
with radiation necrosis, and this was histologically
confirmed. For five patients, only vital tumor tissue was
found; for the others, a mixture of vital tumor tissue
and necrosis was found (example in Supplementary
Fig. 1).PFS. Of the 255 patients with BMs, 204 (80%) pro-
gressed, whereas 589 of 770 patients without BMs
(76.5%) progressed (p ¼ 0.246). The median PFS
times for patients with and without BMs were
Table 1. Baseline Characteristics Overall and Brain Metastases Subgroups
Characteristic
Total
Population
(N ¼ 1025)
Patients without
Baseline Brain
Metastases
(n ¼ 770)
Patients with
Baseline Brain
Metastases
(n ¼ 255) p Valuea
Sex, n (%)
Male 646 (63.0) 488 (63.4) 158 (62.0) 0.685
Median age at start of ICI treatment, y (range) 64.3 (30.2–92.8) 65.4 (30.7–92.8) 61.5 (30.2–80.8) <0.001
Smoking status at start of ICI treatment, n (%)
Current 402 (41.6) 299 (41.2) 103 (42.7) 0.666
Former 488 (50.5) 366 (50.4) 122 (50.7)
Never 77 (8.0) 61 (8.4) 16 (6.6)
Unknown 58 44 14
Histologic type, n (%)
Adenocarcinoma 681 (66.4) 482 (62.6) 199 (78.0) <0.001
Squamous carcinoma 268 (26.2) 230 (29.9) 38 (14.9)
NSCLC, other 76 (7.4) 58 (7.5) 18 (7.1)
Molecular alteration,b n (%)
EGFR mutation (737 tested) 39 (5.3) 29 (5.3) 10 (5.2) 0.921
ALK rearrangement (713 tested) 6 (0.8) 5 (1.0) 1 (0.5) 1.00
KRAS mutation (708 tested) 241 (34.0) 174 (33.6) 67 (35.3) 0.677
BRAF mutation (613 tested) 23 (3.8) 19 (4.3) 4 (2.4) 0.346
ROS1 rearrangement (439 tested) 0 (0.0) 0 (0.0) 0 (0.0) 1.00
PD-L1 status, n (%)
Positive 230 (64.1) 179 (64.9) 51 (61.5) 0.57
Negative 129 (35.9) 97 (35.1) 32 (38.5)
Unknown 666 494 172
Performance status (WHO)
0–1 823 (82.2) 630 (84.0) 197 (77.2) 0.011
2 178 (17.8) 120 (16.0) 58 (25.8)
Unknown 24 20 0
Corticosteroid use at start of ICI treatment, n (%)
Yes 141 (13.9) 72 (9.4) 69 (27.4) <0.001
No 875 (86.1) 692 (90.6) 183 (72.6)
Unknown 9 6 3
Brain imaging 6 weeks of start of ICI treatment, n (%) 534 (52.1) 328 (42.6%) 206 (80.8) <0.001
MRI 172 (32.2) 68 (20.7%) 104 (50.5) <0.001
CT 362 (67.8) 260 (79.35) 102 (49.5)
Median No. of organs with metastases at start of ICI
treatment (range)
2 (1–10) 2 (1–9) 3 (1–10) <0.001
Median line of ICI treatment (range) 2 (1–12) 2 (1–12) 2 (1–8) 0.555
PD-1/PD-L1 inhibitor as monotherapy, n (%) 963 (94.0) 721 (93.6) 242 (94.9) 0.541
PD-1 inhibitor 927 (96.3) 687 (95.3) 240 (99.2) 0.003
PD-L1 inhibitor 36 (3.7) 34 (4.7) 2 (0.8)
aPatients with and without brain metastases are compared.
bPercentage computed for patients with known results, numbers tested (positive or negative) after each molecular alteration.
ICI, immune checkpoint inhibitor; ALK, ALK receptor tyrosine kinase gene; PD-L1, programmed death ligand 1; MRI, magnetic resonance imaging; CT, computed
tomography; PD-1, programmed cell death 1.
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1.9–2.5), respectively (p ¼ 0.009) (Fig. 2A). The pa-
tients with BMs had brain PD significantly more often
than did those without (46.3% versus 11.4% [p <
0.001]). The patients with active BMs had brain PD
(with or without extracranial PD) significantly more
often than did those with stable BMs (54.2% versus
30% [p < 0.001]).
Patterns of progression are depicted in
Supplementary Figure 2. In the subgroup of patientswith BMs, 26 of 204 progressing patients (12.7%) had a
dissociated central nervous system and extracranial
response (i.e., six of 24 patients [25.0%] had brain-only
PD with an extracranial response at that time, and 20
of 97 patients had only extracranial PD but had a cranial
response at that time [seven (35.0%) of these had un-
dergone cranial radiotherapy less than 3 months before
starting ICI treatment]).
In multivariate analysis for PFS, smoking was asso-
ciated with an improved PFS, whereas more than two
Table 2. Baseline Characteristics of Patients with Stable versus Active Brain Metastases
Characteristic
Patients with
Baseline Brain
Metastases
(n ¼ 255)
Patients with
Active Baseline
Brain Metastases
(n ¼ 100)
Patients with
Stable Baseline
Brain Metastases
(n ¼ 121) p Valuea
Median time between first diagnosis of brain
metastases and start of ICI treatment, mo (range)
5.8 (0–68.8) 4.7 (0–41.1) 6.0 (0.1–68.8) 0.248
Brain surgery before start of ICI treatment, n (%) 36 (14.1) 9 (9.0) 23 (19.0) 0.035
Brain radiotherapy before start of ICI treatment, n (%) 173 (68.1) 43 (43.0) 110 (90.9) < 0.001
WBRT 72 (41.6) 18 (41.9) 44 (40.0) 0.664
SRT 99 (57.2) 24 (55.8) 65 (59.1)
WBRT þ boost SRT 2 (1.2) 1 (2.3) 1 (0.9)
Median time between end of last brain radiotherapy
and start of ICI treatment, mo (range)
3.6 (0–66.3) 5.2 (1.7–38.9) 1.4 (0–66.3) <0.001
Brain imaging before start of ICI treatment, n (%) 206 (80.8) 96 (87.3) 121 (100.0) < 0.001
MRI 104 (50.5) 53 (53.0) 59 (48.8) 0.316
CT 102 (49.5) 47 (47.0) 59 (48.8)
Unknown CT or MRI 0 0 3 (2.5)
Brain metastases at start of ICI treatment, n (%)
2 120 (47.1) 52 (52.0) 57 (47.1) 0.769
3–5 49 (19.2) 18 (18.0) 24 (19.8)
6 86 (33.7) 30 (30.0) 40 (33.1)
Brain metastases symptomatic at start of
ICI treatment, n (%)
Yes 37 (14.7) 12 (12.0) 22 (18.5) 0.187
No 214 (85.3) 88 (88.0) 97 (81.5)
Unknown 4 0 2
Corticosteroid use at start of ICI treatment, n (%) 69 (27.4) 22 (22.0) 39 (32.2) 0.100
10 mg of prednisolone equivalent/d 20 (33.3) 6 (31.6) 10 (29.4) 0.869
>10 mg of prednisolone equivalent/d 40 (66.7) 13 (68.4) 24 (70.6)
Unknown dose 9 3 5
WHO PS at start of ICI treatment, n (%)
0–1 197 (77.3) 73 (73.0) 98 (81.0) 0.158
2 58 (22.7) 27 (27.0) 23 (19.0)
ds-GPA at start of ICI treatment, n (%)
0–1 86 (35.7) 33 (33.3) 43 (36.8) 0.869
1.5–2.5 141 (58.5) 60 (60.6) 67 (57.2)
3 14 (5.8) 6 (6.1) 7 (6.0)
3.5–4 0 (0) (0) (0)
Unknown 14 1 4
aPatients with stable and active brain metastases are compared.
ICI, immune checkpoint inhibitor; WBRT, whole brain radiotherapy; SRT, stereotactic radiotherapy; MRI, magnetic resonance imaging; CT, computed tomog-
raphy; PS, performance status; ds-GPA, disease-specific Graded Prognostic Assessment.
July 2019 Outcome of NSCLC with BMs Treated with ICIs 1249organs with metastases, a WHO PS of 2 or higher, and
use of corticosteroids at the start of ICI treatment were
associated with a decreased PFS (Table 3). The results
regarding presence of BM (not associated with PFS) did
not change significantly when we analyzed the subgroup
with baseline brain imaging only (Supplementary
Table 2)
For ds-GPA classifications of 0 to 1, 1.5 to 2.5, and 3,
the median PFS times were 1.4 months (95% CI: 1.2–
1.6), 2.4 months (95% CI: 1.5–3.3), and 5.5 months (95%
CI: 0.1–11.8), respectively. The median PFS was signifi-
cantly longer for ds-GPA classifications of 1.5 to 2.5 (p <
0.001) and 3 (p ¼ 0.023) than for classification of 0 to 1.
In multivariate analysis for the BM subgroup, more thantwo organs with metastases, and use of corticosteroids
at the start of ICI treatment were associated with poorer
PFS, whereas stable BM and a higher ds-GPA score were
associated with improved PFS (Table 4). Previous cranial
radiotherapy (yes versus no) was not associated with
PFS in univariate analysis (HR ¼ 0.80, 95% CI: 0.60–
1.08, p ¼ 0.144) and as such was not carried forward to
multivariate analysis.
OS. The median OS times were 8.6 months (95% CI: 6.8–
12.0) for patients with BMs and 11.4 months (95% CI:
8.6–13.8) for patients without BMs, respectively (p ¼
0.035) (Fig. 2B). Except for smoking, the same factors
associated with PFS in multivariate analysis were
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Figure 2. Kaplan-Meier curves for progression-free survival (A) and overall survival (B) according to presence of brain me-
tastases. met, metastasis.
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with OS in multivariate analysis (see Table 3). The re-
sults did not change significantly regarding presence of
BMs when we analyzed the subgroup with baseline brain
imaging only (see Supplementary Table 2). Because of
the large number of patients with unknown PD-L1 status
(65.0%), PD-L1 status was not evaluated in the multi-
variate analysis.
The median OS times were 4.4 months (95% CI: 2.0–
6.7), 13.7 months (95% CI: 10.2–17.2), and 13.7 months
(95% CI: 1.5–26.1) for ds-GPA classifications of 0 to 1,
1.5 to 2.5, and 3, respectively. The median OS was
significantly longer with ds-GPA classifications of 1.5 to
2.5 (p < 0.001) and 3 (p ¼ 0.010) than with classifica-
tions of 0 to 1. In multivariate analysis for the BM
subgroup, use of corticosteroids at the start of ICI
treatment was associated with poorer PFS, whereas
stable BMs and a higher ds-GPA score were associated
with improved PFS (see Table 4). Previous cranial
radiotherapy (yes versus no) was not associated with
survival in univariate analysis (HR ¼ 0.80, 95% CI:
0.57–1.13, p ¼ 0.204) and as such was not carried for-
ward to multivariate analysis.Discussion
BMs are frequent in NSCLC, but patients with BMs are
often fully excluded from clinical trials, or only selected
patients are included, resulting in underrepresentation
of these patients in clinical trials (6.2%–17.5% of
included patients had BMs).2–13 EAPs also allowed only
selected patients with BMs.23,24 As data on ICI efficacy in
less-selected patients with BMs are lacking, we per-
formed the current study to evaluate response and
survival of patients with BMs treated with ICIs.In this large, multicenter cohort of patients with
advanced ICI-treated NSCLC, 255 (24.9%) had BMs at the
start of ICI treatment. This percentage is higher than that
reported in clinical trials (6.2%–17.5%) but comparable
with the rates reported in other, mostly smaller retro-
spective ICI series (10.2%–31%)2,3,5,7–9,13,22,23,25,26 and
in line with what is expected in this patient population
(25%–40% with BMs).31,32 To the best of our knowledge,
only two large EAP series on patients with NSCLC and
BMs treated with ICIs have previously been reported,23,25
with 26% (409 of 1588) and 22% (197 of 902) of pa-
tients with BMs included, respectively. Important factors
for patients with BMs such as ds-GPA score, use of ste-
roids and classification of BM (active or not) were not
mentioned. In our study, 39.2% of patients with BMs had
active BMs, 14.7% had symptomatic BMs, 22.7% had a
WHO PS of 2 or higher, and 15.7% had corticosteroid
doses higher than 10 mg of prednisolone equivalent/day
(all exclusion criteria in EAP or clinical trial).
The overall ORR of 20.6% (with BMs) to 22.7% (no
BMs) in our series is comparable with that in the existing
literature.2,3,8 The 27.3% intracranial ORR of the patients
with active BMs is similar to that of the PD-L1–positive
patients included in the phase II trial of Goldberg et al.
(none of the PD-L1–negative patients responded in this
trial),18 and is slightly higher than that reported in
retrospective series.20,23,26 Furthermore, patients with
BMs progressed more often in the brain than did pa-
tients without preexisting BMs. As severe neurological
symptoms can develop in these patients because of their
brain progression, careful monitoring, especially of
active BM, during the first months of ICI treatment
seems needed. In general, a growing BM indicates real
PD, as pseudoprogression was rare (0.8%) in our BM
cohort.
Table 3. Multivariate Analysis of PFS and OS of the Overall Population
Factor PFS HR (95% CI) p Value OS HR (95% CI) p Value
Age, >65 y vs. 65 y 1.03 (0.89–1.20) 0.667 1.11 (0.93–1.33) 0.26
Smoking, yes vs. no 0.52 (0.41–0.67) <0.0001 0.79 (0.59–1.06) 0.112
Histologic type
Squamous vs. adeno 1.04 (0.87–1.24) 0.86 1.18 (0.95–1.45) 0.28
NSCLC, other vs. adeno 1.06 (0.80–1.42) 1.14 (0.81–1.60)
No. of organs with metastases, >2 vs. 2 1.29 (1.10–1.50) 0.001 1.42 (1.18–1.71) <0.0001
ICI line, >2 vs. 2 1.01 (0.87–1.18) 0.881 1.07 (0.90–1.29) 0.44
WHO PS, 2 vs. 0–1 2.29 (1.89–2.77) <0.0001 3.37 (2.72–4.16) <0.0001
Use of corticosteroids, yes vs. no 1.31 (1.07–1.62) 0.01 1.46 (1.16–1.84) 0.001
Brain metastases, yes vs. no 1.10 (0.92–1.31) 0.28 0.99 (0.81–1.23) 0.96
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; adeno, adenocarcinoma; ICI, immune checkpoint inhibitor; PS,
performance status.
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our study are comparable with those in other, mostly
smaller ICI series.18,20–25 The median PFS and OS times
were shorter for patients with BMs than for those
without BMs, but in multivariate analysis presence of
BMs (when compared with absence of BMs) was not
significantly associated with a poorer survival with ICI
treatment. This finding is in contrast to the findings of
the French EAP series, but in the French series there was
no adjustment for corticosteroid use or number of or-
gans with metastases in multivariate analysis,25 which
were both associated with poorer PFS and OS in our and
in other series.15,33
Patients with stable BMs had PFS and OS times su-
perior to those of patients with active BMs; use of cor-
ticosteroids at the start of ICI treatment was associated
with worse PFS and OS. Furthermore, symptomatic BMs
were associated with worse PFS and OS in univariate
analysis (for PFS, HR ¼ 1.90, 95% CI: 1.30–2.77, p ¼
0.001; and for OS, HR ¼ 2.03, 95% CI: 1.33–3.11, p ¼
0.001). Corticosteroid use at the start of ICI treatment
was already described as deleterious.15,34 However, as
there was colinearity with symptomatic BMs and use ofTable 4. Multivariate Analysis of PFS and OS in the BM Subgro
Factor PFS
Sex, male vs. female 0.95
Smoking, yes vs. no 0.81
Histologic type
Squamous vs. adeno 0.97
NSCLC, other vs. adeno 0.98
No. of organs with metastases, >2 vs. 2 1.72
ICI treatment line, >2 vs. 2 0.98
Use of corticosteroids at start of ICI treatment, yes vs. no 2.78
BMs stable at start ICI, yes vs. no 0.62
ds-GPA, 1.5–2.5 vs. 0–1 0.55
ds-GPA, 3 vs. 0–1 0.65
BM, brain metastasis; PFS, progression free survival; HR, hazard ratio; CI, confid
disease-specific Graded Prognostic Assessment.corticosteroids and use of corticosteroids was more
significant, only the latter was carried forward to the
multivariate analysis. Interestingly, ds-GPA score is
prognostic not only patients with in newly diagnosed
BMs28 but also in patients with previously diagnosed
BMs who start ICI treatment. ds-GPA score combined
with use of corticosteroids, symptoms, BM status (active
versus stable), and PD-L1 status could be used in the
decision regarding whether to administer ICI to a patient
with BM.
In our study, cranial radiotherapy before start of ICI
treatment (yes versus no) was not associated with OS in
the BM subgroup in univariate analysis (HR ¼ 0.80, 95%
CI: 0.57–1.13, p ¼ 0.204); however, this analysis did not
take into account time from cranial radiotherapy to start
of ICI treatment, or brain PD after cranial irradiation
before the start of ICI treatment. Indeed, patients with
stable BMs (i.e., locally treated [mostly with radio-
therapy] and no radiological progression or new BMs at
the start of ICI treatment) had a better OS than did those
with active BM. In a retrospective, single-center (N ¼ 98)
analysis of the KEYNOTE-001 trial, patients who were
treated with any radiotherapy (n ¼ 42) or extracranialup
HR (95% CI) p Value OS HR (95% CI) p Value
(0.68–1.33) 0.765 1.42 (0.94–2.16) 0.100
(0.40–1.64) 0.561 0.74 (0.34–1.64) 0.464
(0.60–1.57) 0.99 1.09 (0.63–1.90) 0.750
(0.53–1.83) 0.79 (0.38–1.65)
(1.15–2.57) 0.009 1.39 (0.87–2.22) 0.174
(0.70–1.39) 0.922 1.09 (0.73–1.65) 0.671
(1.90–4.08) <0.0001 2.37 (1.54–3.63) <0.0001
(0.44–0.88) 0.007 0.62 (0.41–0.93) 0.019
(0.38–0.78) 0.004 0.48 (0.31–0.72) 0.002
(0.31–1.35) 0.54 (0.22–1.32)
ence interval; OS, overall survival; ICI, immune checkpoint inhibitor; ds-GPA,
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had a survival superior to that of patients who were not
treated with radiotherapy.35 However, an updated
analysis including all patients included in the KEYNOTE-
001 trial did not demonstrate this benefit anymore.36 As
it is possible that recent cranial irradiation before the
start of ICI treatment improves the survival of patients
with BMs treated with ICIs owing to improved local
control, we divided (in an exploratory analysis) the
stable BM group (i.e., those with local brain therapy
before the start of ICI treatment, regardless of timing of
local treatment before ICI treatment, but without brain
progression on brain imaging before ICI) into (1) stable
patients without cranial irradiation within 3 months of
ICI treatment and (2) stable patients who received cra-
nial irradiation within 3 months of ICI treatment. When
compared to active BMs, cranial irradiation within 3
months of the start of ICI treatment was associated
with a superior survival (HR ¼ 0.52, 95% CI: 0.30–0.72,
p ¼ 0.04), whereas no cranial irradiation within 3
months of the start of ICI treatment was not
(Supplementary Table 3).
The drawbacks of the current study are inherent to
the retrospective data collection, although the overview
of patients who received an ICI was prospectively
collected. Not all patients underwent baseline brain im-
aging, and the reasons for brain imaging varied. How-
ever, when we analyzed the subgroup with baseline
brain imaging only, the results did not change signifi-
cantly. Furthermore, follow-up was not standardized,
and imaging was not reviewed according to the
Response Criteria in Solid Tumors 1.1/Response
Assessment in Neuro-oncology BM criteria (the differ-
ences between response assessment methods are sum-
marized in El Rassy et al.37). The definition of active BM
was according to Goldberg et al.,30 but the decision to
administer local treatment for BM before ICI treatment
was according to the treating physician, making the
stable BM group more heterogeneous. The number of
patients with active BMs who had cranial response
evaluation during ICI treatment was small, and for most
of these patients PD-L1 status was unknown, making
further subgroup analysis of the active BM group diffi-
cult. Moreover, additional data such as steroid dosage or
type and severity of neurological symptoms would have
enabled further subgroup analyses. As whether neuro-
logical adverse events were to be attributed to immu-
notherapy, previous cranial radiotherapy, or brain
progression was not always clear, we choose not to
report these events. Cause of death (cranial versus
extracranial progression) was not documented for most
patients. We could not evaluate the possible different
efficacy of PD-1/PD-L1 inhibitors in relation to BMs, asonly two patients with BMs were treated with PD-L1
inhibition monotherapy. Lastly, we did not use the up-
date of the ds-GPA for lung cancer (the molecular GPA,38
also incorporating the presence of EGFR and ALK re-
ceptor tyrosine kinase gene [ALK] drivers in the non-
squamous subgroup). However, this molecular GPA was
validated in patients with newly diagnosed BMs. Patients
with driver mutations included in the molecular GPA
analysis would have had the option of receiving effective
targeted therapy, improving their OS (patients with
driver mutations had the best survival in the molecular
GPA).38 In contrast, patients with driver mutations often
have a poor survival when treated with an ICI.39–41
Therefore, we choose to use the ds-GPA instead of the
molecular GPA.
In conclusion, in multivariate analysis, the presence
of BM was not associated with response and survival
when treated with an ICI. Patients with (untreated) BM,
a good ds-GPA classification, and no requirement for
corticosteroids should not be excluded from clinical tri-
als, although especially those patients with active BM
should undergo regular brain imaging, as brain pro-
gression occurs more frequently in this subgroup of
patients. Future studies should also focus on the timing
of cranial irradiation, as cranial irradiation within 3
months of the start of ICI treatment was associated with
improved OS compared with cranial irradiation more
than 3 months before the start of ICI treatment.
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